Tacrolimus is routinely administered for GVHD prophylaxis as a 24-h continuous infusion that requires a dedicated i.v. line and thus becomes logistically difficult to administer, especially in young pediatric patients. We investigated the safety and efficacy of twice daily bolus infusions of i.v. tacrolimus in 33 children undergoing hematopoietic stem cell transplantation (HSCT) at our institution. Tacrolimus was started at an initial dose of 0.015 mg/kg i.v. bolus administered as a 2-h infusion and then given at every 12 h to maintain a trough drug level between 5-15 ng/mL. Patients also received short-course MTX (66%) or mycophenolate mofetil (34%) in combination with tacrolimus. No acute infusional toxicities were observed with bolus infusions of i.v. tacrolimus. Nephrotoxicity occurred in 14/33 (42%) patients and 48% developed hypertension (HT). Almost all (94%) patients required magnesium supplements to maintain magnesium (Mg) levels X1.5 mg/dL. In all, 3 (9%) patients developed severe sinusoidal obstruction syndrome (SOS). One patient developed posterior reversible leuko-encephalopathy syndrome (PRES) and one additional patient had tremors. The prevelance of these side-effects was similar to those reported for continuous i.v. administration. In all, 28% of the evaluable patients developed acute GVHDXgrade II, though the incidence of severe (grade III-IV) GVHD was only 7%. These results suggest that intermittent bolus i.v. tacrolimus administration is a safe and effective method of GVHD prophylaxis in children.
INTRODUCTION
Tacrolimus (FK506) is a heterocyclic macrolide antibiotic isolated from the broth of soil fungus Streptomyces tsukubaensis. 1 It inhibits calcineurin, resulting in the inhibition of interleukin-2 production and decreased proliferation of ag-specific T-lymphocytes. 2 It has significant efficacy in preventing GVHD in both related and unrelated donor hematopoietic stem cell transplantation (HSCT). 3, 4 In two randomized human trials, tacrolimus in combination with standard dose MTX was associated with a significantly lower incidence of acute GVHD (aGVHD) compared with cyclosporine (CSP) and MTX combination. 4, 5 Currently in the HSCT setting, the recommended method of administration of i.v. tacrolimus is as a continuous 24 h infusion of 0.03-0.04 mg/kg per day, usually starting on day -2 of HSCT; with the aim to maintain random whole-blood tacrolimus concentration of 5-15 ng/mL (Liquid chromatography-tandem mass spectrometric assay) or 8-20 ng/mL (chemiluminescent immunoassay technique, Abbott Diagnostics, Abbott Park, IL, USA). [6] [7] [8] Common adverse effects of tacrolimus are hyperglycemia, hypomagnesemia, nephrotoxicity, hypertension (HT) and tremors. Worsening renal dysfunction, HT and severe neurotoxicity (seizures, leucoencephalopathy, hallucinations and cortical blindness) are reported with increased blood concentrations. 9 A dedicated central venous line is required for the continuous infusion of tacrolimus and this reduces the number of ports available for administration of other medications and transfusions, necessitating the use of additional central lines in children. This logistic difficulty leads many pediatric HSCT centers not to routinely use this potentially efficacious drug for GVHD prophylaxis. We report here our experience with the use of intermittent (every 12 h) bolus dosing of i.v. tacrolimus in pediatric patients.
PATIENTS AND METHODS Patients
Data were collected retrospectively on 33/70 (47%) pediatric patients undergoing allogeneic HSCT and receiving bolus i.v. tacrolimus at Nationwide Children's Hospital from March 2006 to December 2009. Patients who received i.v. bolus tacrolimus were not on a therapeutic study requiring CSP. The study examined the efficacy and safety of i.v. bolus infusion of tacrolimus and prevelance of aGVHD. The study was approved by the Nationwide Children's Hospital Institutional Review Board. HLA typing was performed by high resolution DNA typing for HLA-A, B, C, DRB1 and DQ for all unrelated donors and HLA-A, B and DRB1 for related donors. HLA tying was done at the intermediate level for Class 1 antigens and at high resolution for DRB1 for cord blood selection.
Tacrolimus administration
All patients received twice daily bolus infusions of i.v. tacrolimus for GVHD prophylaxis. Tacrolimus started at an initial dose of 0.015 mg/kg i.v. bolus administered as a 2-h infusion beginning on day -2 or -3 and then given at every 12 h to simulate the oral dosing schedule. Trough drug levels were drawn from a 'non-tacrolimus' dedicated in dwelling central venous line before the fifth dose and then monitored twice weekly. The tacrolimus dose was adjusted to maintain a trough whole-blood drug level range between 5 and.15 ng/mL (Liquid chromatography-tandem mass spectrometric assay). Bolus i.v. tacrolimus infusions were continued until patients were transferred to the oral route. All patients included in the analysis received bolus doses of i.v. tacrolimus along with standard i.v. MTX (15 mg/m 2 on day þ 1; 10 mg/m 2 on days 3, 6, ± 11) or mycophenolate mofetil (MMF, 15 mg/kg per dose, maximum 1 g every 8 h). GVHD was graded according to the Seattle consensus criteria. 10 
Toxicity assessment
Specific toxicities studied included nephrotoxicity, defined as X2 Â baseline creatinine at any time point during bolus i.v. tacrolimus prophylaxis; HT, defined as persistent increase in systolic or diastolic blood pressure495th percentile for age for 3 consecutive days or addition of an anti-hypertensive medication; posterior reversible leuko-encephalopathy syndrome (PRES), defined as any evidence of altered sensorium with seizure activity accompanied by characterisitic changes on head magnetic resonance imaging; 11 hypomagnesemia, defined as Mg levels o1.5 mg/dL or requirement of Mg supplementation to maintain MgX1.5 mg/dL; and hepatotoxicity, defined as X3 Â the baseline liver enzyme levels. Thrombotic thrombocytopenic purpura and sinusoidal obstruction syndrome (SOS) were diagnosed based on standard published criteria.
12,13 CMV reactivation was defined as 41000 copies of the virus by real-time PCR or initiation of pre-emptive treatment at any time point.
RESULTS
Thirty-three patients received bolus i.v. tacrolimus and were included in the analysis. The majority of the children were transplanted for malignant disorders and four children received HSCT for non-malignant diseases. Patient characteristics are shown in Table 1 . Median age of recipients was 10 years (range:14 months-17 years). In all, 21 (64%) patients received unrelated grafts (10/10 or 9/10 HLA-matched) and 12 (36%) received a matched related donor HSCT. BM was the most common stem cell source utilized (66%) and 8 patients (24%) received granulocyte colony-stimulating factor-mobilized peripheral blood. The majority of the patients (66%) received short-course MTX in combination with i.v. tacrolimus for their GVHD prophylaxis. In all, 14 (42%) patients received rabbit anti-thymocyte globulin (Thymoglobulin, Genzyme, Cambridge, MA, USA, total dose 5-10 mg/kg) as part of the preparative regimen. Diverse conditioning regimens were used as shown in Table 1 . Most (26) of the children received myeloablative preparative regimens, either chemotherapy or TBI based. Seven patients received reduced intensity preparative regimens.
All bolus infusions of tacrolimus were well tolerated, without any acute infusional toxicity observed. Incidence of various toxicities is shown in Table 2 . Nephrotoxicty was detected in 14 (42%) patients. Most of these patients were also receiving other potentially nephrotoxic medications for example, antibiotics, acyclovir and antifungal agents concurrently. No patient required dialysis. No patient developed thrombotic thrombocytopenic purpura. In all, 16 (48%) patients developed HT requiring medical intervention that continued throughout the tacrolimus course. Hypomagnesemia was detected in almost all of the patients (94%), but responded to oral or i.v. Mg supplementation. In all, 3 (9%) patients developed severe SOS requiring treatment with i.v. defebrotide. One patient developed PRES (grade 4 neurotoxicity) and one additional patient developed severe tremors alone. Tacrolimus was suspended for 4 days for the patient with PRES and there was no recurrence of tremors on restarting the drug. Of the 21 patients at risk for CMV reactivation (patient and/or donor status CMV Immunoglobulin G positive), only 2 (9%) required preemptive treatment for CMV reactivation and no CMV disease was observed.
Graft rejection occurred in two patients and was attributed to leukemia relapse in one patient and viral illness in another patient with sickle cell disease. One patient died because of sepsis and two patients died due to relapse before day þ 100. Therefore 28 patients were evaluable for the analysis of aGVHD. Grade II-IV aGVHD was observed in 8 (28%) patients. Only 2 patients (7%) had severe (Grade III-IV) aGVHD; both these patients received mismatched unrelated donor peripheral blood stem cells for refractory malignancies. In all, 7 (25%) patients developed some form of chronic GVHD. The relapse rate was 30%.
DISCUSSION
The major deterrents to bolus intermittent dosing of i.v. tacrolimus are the fear of toxicity due to increased peak levels of the drug and loss of efficacy in preventing GVHD due to low troughs; hence, continuous i.v. infusion is the recommended mode of administration.
14 This requires a dedicated i.v. line for drug administration making tacrolimus use logistically difficult in young children. We used i.v. bolus infusions of tacrolimus over 2 h given every 12 h for GVHD prophylaxis that takes away the requirement of a dedicated central venous line in children. Our results suggest that bolus infusions of i.v. tacrolimus can be easily infused without increased toxicity or loss of efficacy in preventing GVHD.
Our patient population demonstrated less nephrotoxicity (42%) compared with prior reports. Past studies of continuous infusion of tacrolimus and CSP report nephrotoxicity rates of 60-80% using the same toxicity criteria. 4, 5, 15 Sixteen percent of the adult patients needed dialysis in a prior study using continuous i.v. tacrolimus and MTX. 5 None of the patients required dialysis or developed thrombotic thrombocytopenic purpura in our cohort that received bolus i.v. tacrolimus. HT occurred in almost half of the patients, but responded to anti-hypertensive medications that were given concurrently. HT incidence is reported to be in a similar range (45-63%) in solid-organ transplant patients and HSCT patients receiving continuous i.v. tacrolimus. 15 In patients receiving bolusdose CSP, the HT rate is reported as 32%. 5 Hypomagnesemia occurs in 16-48% transplant patients receiving continuous i.v. tacrolimus for solid-organ transplants. 16 In the randomized control trials of continuous tacrolimus and bolus-dose CSP, rates of hypomagnesemia were similar. 4, 5 This was the most common toxicity associated with bolus tacrolimus use, with almost all children requiring Mg supplementation, though this is not different from our limited experience of continuous tacrolimus administration in children. The higher incidence of hypomagnesemia may be related to increased vigilance for magnesium levels in children. In all, 3 (9%) patients developed severe SOS and continued on bolus tacrolimus administration for GVHD prophylaxis during the treatment with i.v. defibrotide. All three patients responded and survived the SOS episodes. An earlier study of continuous i.v. tacrolimus and MTX administration reported a 21% incidence of severe SOS. 5 Mild neurotoxicity (headache, tremors, paresthesia and insomnia) is reported to occur in 19-64% of solid-organ transplant patients. 17, 18 Moderate to severe neurotoxicity (seizures, confusion, PRES and cortical blindness) can occur in upto 20-32% patients. 19, 20 A 9% incidence of neurotoxicity has been seen in the pediatric population using continuous i.v. tacrolimus in combination with mycophenolate mofetil and 16% in those receiving CSP. 5, 21 Only 1 (3%) of our patients developed PRES requiring discontinuation of tacrolimus. One additional patient developed tremors (mild neurotoxicity) associated with tacrolimus; however, this patient did not require discontinuation of the drug. This suggests a low incidence of neurotoxicity with i.v. bolus administration. The incidence of CMV reactivation (9%) in our patients is also similar to the reported incidence of reactivation in pediatric population and was not increased inspite of 42% of the patients receiving rabbit antithymocyte globulin (total dose 5-10 mg/kg) along with bolus i.v. tacrolimus.
Though the lower incidence of toxicities (especially, renal, hepatic and neurological) in this report is probably related to the younger age group compared with data reported in prior studies in adults, the incidence of toxicity appears to be no higher than that reported with continuous i.v. administration of tacrolimus. 7, 21 Tacrolimus is a proven immunosuppressant effective in the prevention of aGVHD in children. The incidence of aGVHDXGrade II in this study (28%) is similar to the reported incidence of aGVHD in pediatric population using both related and unrelated donors with a variety of GVHD prophylaxis. 22, 23 The probability of developing XGrade II aGVHD was reported as 45% in the pediatric population after continuous i.v. tacrolimus and mycophenolate mofetil as prophylaxis. 21 Lower incidence in our population could also be related to better HLA matching and antithymocyte globulin use. Only 2 (7%) of the patients receiving bolus tacrolimus infusions developed grade III-IV aGVHD and both these patients received mis-matched unrelated donor G-CSF stimulated peripheral blood stem cells for refractory malignancies. We did not see any increased incidence of aGVHD, chronic GVHD or relapse in our population, showing that the bolus dosing is at least as efficacious as continuous dose tacrolimus.
Given that access to central venous lines is an important issue in children, intermittent bolus dosing of tacrolimus eases the requirements of a dedicated i.v. line. Further studies are warranted to confirm the safety and efficacy of intermittent tacrolimus administration.
